Letters from Readers

Feb 1, 1996

Troglitazone is a new insulin-action enhancer currently in the third phase of clinical testing. Parke-Davis Pharmaceutical Research has announced that a pilot study at St. Joseph Hospital in Ann Arbor, Mich., showed that the drug lowers blood glucose levels in patients with type 2 diabetes. The study also found that the drug can help reduce and even eliminate daily insulin injections in type 2 diabetics.

Troglitazone was given to 17 patients who were not able to control their type 2 diabetes with diet or oral medications and whose blood glucose levels fluctuated even with insulin therapy. Within 12 weeks, the patients were able to decrease their insulin dosages an average of 65%. Seven of the participants were able to completely discontinue their insulin regimen, and after the study concluded, two more patients were able to quit using insulin while taking troglitazone.

Jeffrey Sanfield, MD, principal investigator of the study, says, "An insulin action enhancer like troglitazone could go a long way in helping people control their diabetes, as well as reducing associated healthcare costs."

The drug was codeveloped by Parke-Davis Pharmaceutical Research, a division of Sankyo U.S.A. and Warner-Lambert Company. Several studies of troglitazone are taking place, and the drug will most likely be presented to the FDA sometime in 1996.

Click Here To View Or Post Comments

Categories: Blood Glucose, Diabetes, Insulin, Letters to the Editor, Medications Research, Type 2 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.